ABBV
Abbvie Inc
NYSE · Biotechnology
$223.43
+4.41 (+2.01%)
S&P 500
Mega-Cap Stocks
Blue Chip Stocks
Biotech Stocks
Healthcare Stocks
Best Dividend Stocks
Highest Dividend Yield
ABBV News2 articles
AbbVie Gains on Moody's Credit Upgrade, Focus Shifts to Immunology Portfolio
AbbVie shares rose 2% to $223.43 after Moody's upgraded its credit rating to A2 with a stable outlook. Investors now watch demand and pricing for Skyrizi and Rinvoq amid Humira competition.
AbbVie Shares Gain 2% to Close Near $223 Amid Earnings Volatility, Credit Upgrade
AbbVie stock rose 2% Friday, ending a turbulent week marked by earnings scrutiny and a Moody's credit rating upgrade. Investors remain focused on Skyrizi and Rinvoq growth amid competitive pressures.